# AstraZeneca and GSK beat first quarter earnings forecasts, driven by strong cancer and HIV drugs.

*biotech · news · 2026-04-29 · CNBC TV18*

## Key points

- AstraZeneca's Q1 earnings per share were $2.58, surpassing analyst forecasts.
- Strong sales of Imfinzi and other oncology drugs support AstraZeneca's $80 billion revenue target by 2030.
- GSK's Q1 adjusted earnings rose to 46.5 pence, exceeding estimates of 43.2 pence.
- GSK's stock rose nearly 34% following the announcement of Luke Miels as incoming CEO.

**Companies:** AstraZeneca, GSK
**Countries:** United Kingdom

[Read the full story on CNBC TV18](https://www.cnbctv18.com/market/astrazeneca-gsk-profit-rises-on-strong-sales-of-crucial-cancer-drugs-ws-el-19895598.htm)

---

Canonical: https://newsio.io/n/f2fe126d-7225-4797-a6f9-edbf9c4b2a69/astrazeneca-and-gsk-beat-first-quarter-earnings-forecasts-driven-by-strong-cance
Summarized by Newsio from CNBC TV18. https://newsio.io/how-it-works